{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-25-000009","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.180695+00:00","generated_at":"2026-05-27T00:02:39.524453+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inspire Medical Q4 revenue $239.7M (+25% YoY); EPS $1.15; guides FY2025 rev $940-955M","bullets":["Q4 revenue $239.7M (+25% YoY); net income $35.2M, diluted EPS $1.15 vs $0.49 prior year.","Full year 2024 revenue $802.8M (+28% YoY); net income $53.5M ($1.75 diluted EPS) vs net loss in 2023.","FY2025 guidance: revenue $940-955M (17-19% growth); diluted EPS $2.10-$2.20.","Added 72 U.S. centers in Q4 (total 1,435); U.S. sales territories now 335; over 90,000 patients treated.","Initiated $75M accelerated share repurchase program; operating cash flow $130.2M for full year."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-25-000009","json":"https://secwatch.observer/filing/0001609550-25-000009.json","markdown":"https://secwatch.observer/filing/0001609550-25-000009.md","text":"https://secwatch.observer/filing/0001609550-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955025000009/0001609550-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955025000009/insp-20250210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:02:39.524453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}